Work

Drug‐induced liver injury from Deferasirox in a pediatric patient with hereditary spherocytosis: A case report

Year: 2024

Type: article

Abstract: Patients with hereditary spherocytosis (HS) often require red blood cell transfusions for the treatment of hemolytic anemia. Iron overload is a known complication of frequent transfusions. Deferasirox, an oral iron chelator, can cause transient elevations in serum aminotransferase levels. There have been a few cases demonstrating Deferasirox-associated liver injury in patients with sickle cell anemia and thalassemia. In this case report, we present a 13-year-old male with transfusion-dependent HS treated with Deferasirox who presented with jaundice and was found to have evidence of acute hepatocellular injury.

Source: JPGN Reports

DOI: 10.1002/jpr3.12155

Authors: Siddhant Talwar, Blake Rosenthal, Madhav Vissa, Kayla Cort, Joshua Byers, Sabina Ali

Institutions: University of California, San Francisco, UCSF Benioff Children's Hospital, Children's Hospital of Los Angeles, University of California San Francisco Medical Center

Language: English

Topic: Drug-Induced Hepatotoxicity and Protection

Subfield: Pharmacology

Field: Pharmacology, Toxicology and Pharmaceutics

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $1,900